Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.

Ibiayi Dagogo-Jack Geoffrey R OxnardMakenzi EvangelistSubba R DigumarthyJessica J Lin Justin F GainorJohn F MurphyMichael S RabinRebecca S Heist Alona Muzikansky Alice T Shaw

Published in: JCO precision oncology (2022)

Lorlatinib induced durable intracranial disease control in patients with CNS-only relapse on second-generation ALK inhibitors, suggesting that tumors with CNS-limited progression on brain-penetrant ALK tyrosine kinase inhibitors remain ALK-dependent.

Keyphrases

phase ii study
advanced non small cell lung cancer
blood brain barrier
open label
free survival
locally advanced
high glucose
diffuse large b cell lymphoma
diabetic rats
epidermal growth factor receptor
resting state
tyrosine kinase
drug induced
placebo controlled
rectal cancer